At Sheba Medical Center, a first-of-its-kind study in the world will be launched tomorrow (Monday), in which a fourth vaccine will be given in order to test the effectiveness of the fourth dose.
The study was supposed to start a week ago, but only today was it approved by the Helsinki Commission.
The study is based on the serology and immunity of the world's largest group of subjects (cohort), numbering about 6,000 people.
The fourth vaccine study will involve about 150 health workers from Sheba, who received the third dose by August 20, 2021 and their serology result is below 700.
The experiment, conducted in collaboration with the Ministry of Health, was approved by the Helsinki Committee - the highest committee for experiments on humans.
The study will be led by Sheba, Prof. Gili Regev-Yohai, director of the Infection Prevention and Control Unit.
"In this study, we will examine the effect of the fourth vaccine on antibody levels, on disease prevention and examine safety," said Prof. Regev.
"This study is expected to shed light on the additional benefit of giving a fourth dose, we will understand whether and to whom it is worth giving a fourth dose. .
Chairman of the IDF, Photo: Yossi Zeliger
The decision regarding the fourth vaccine was made as a "besieged decision" according to Dr. Lev, head of the epidemiology team. It is unclear when it will be implemented and when the vaccine will start, due to the fact that it has not yet been approved by the director general of the Ministry of Health.
"We have made the decision now so as not to convene the team every day. We see where the numbers are going and they will not be stopped at the sword. If we make a decision that this disease is really 'fun' then we can drink the decision. That means a besieged decision," explained Dr. heart.
Were we wrong?
Fixed!
If you found an error in the article, we'll be happy for you to share it with us